A carregar...
Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib
BACKGROUND: Bevacizumab plus interferon-α2a (IFN) prolongs progression-free survival to >10 months, which is comparable with sunitinib as first-line treatment of metastatic renal cell carcinoma (RCC). The two regimens have different tolerability profiles; therefore, costs for managing adverse eve...
Na minha lista:
| Main Authors: | , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Nature Publishing Group
2010
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2813739/ https://ncbi.nlm.nih.gov/pubmed/19920817 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6605417 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|